SummaryThis study aims to highlight a typical lipid signature able to predict the tumor response to preoperative chemoradiation therapy in advanced rectal cancer by using a lipidomics approach. Five lipids were validated as biomarkers able to predict response before treatment, resulting in a receiver operating characteristic curve characterized by an area under the curve of 0.95. Results suggest serum lipids could represent a useful tool in prediction of chemoradiation therapy response, toward a personalized treatment.

Introduction {#sec1}
============

Colorectal cancer (CRC) is the third most frequently occurring cancer globally.[@bib1] Preoperative fluoropyrimidine-based chemoradiation therapy (CRT) or short-course radiation therapy followed by total mesorectal excision are the standard treatments for CRC.[@bib2], [@bib3], [@bib4] In the effort to personalize treatments, there is increasing interest in predicting which patients will respond to neoadjuvant CRT,[@bib5] especially via investigating easily accessible biological fluids,[@bib6] and in improving response rate and survival outcomes. Several biomarkers have been investigated for their ability to predict outcome in locally advanced rectal cancer (LARC) treated with CRT, but few works have investigated lipids.[@bib7], [@bib8], [@bib9] Bioactive lipids are fundamental mediators of a number of biological processes,[@bib10], [@bib11], [@bib12] and the implication of lipids in cancer growth and diffusion have already been demonstrated.[@bib13] In this work, we aimed to study serum polar lipids in a prospective cohort of LARC patients before CRT (t0 group), including patients naïve to chemotherapy and radiation therapy. Samples were also collected during CRT (t14 and t28 days), in the effort to correlate the global lipid signature to response to treatment.

Methods {#sec2}
=======

See [Appendix E1](#appsec1){ref-type="sec"}, available as supplementary material online only at [www.practicalradon.org](http://www.practicalradon.org){#intref0020}.

Results {#sec3}
=======

Lipidomics biomarker discovery {#sec3.1}
------------------------------

The serum from 18 patients with LARC (7 women, 11 men)---8 of whom were classified as responders (RPs) and 10 as not responders (NRPs) according to Mandard\'s tumor regression grading---treated with preoperative CRT was analyzed by liquid chromatography electrospray ionization tandem mass spectometry. Data were converted into a matrix containing m/z signals coupled with retention time as variables and the patient codes as observations. This dataset was reduced by considering only variables present in at least 50% of patients. [Figure 1](#fig1){ref-type="fig"} shows the lipid classes (including lyso forms) screened. The studied lipids were sphingomyelins (SMs) and phosphatidylcholines (PCs; [Fig 1](#fig1){ref-type="fig"}A), phosphatidylethanolamine ([Fig 1](#fig1){ref-type="fig"}B), phosphatidylglycerols ([Fig 1](#fig1){ref-type="fig"}C), and phosphatidylserines ([Fig 1](#fig1){ref-type="fig"}D). Each lipid class screened was reported. In [Fig 1](#fig1){ref-type="fig"}A, the score plot of phosphatidylcholine/SM phospholipids is shown, whereas [Fig 1](#fig1){ref-type="fig"}B shows the score plot of the phosphatidylethanolamine class; [Fig 1](#fig1){ref-type="fig"}C shows the phosphatidylglycerol lipids; and the phosphatidylserine class is reported in [Fig1D](#fig1){ref-type="fig"}. The resulting PLS-DA models are reported as score scatter plots in [Fig 1](#fig1){ref-type="fig"}, showing clear separation between RP and NRP before treatment. The lipids identified as variable important for the projection (VIP \>1) were confirmed through a univariate test. At t0, 65 lipids were identified as significant, with the criteria of VIP \>1.5 and *P* \< .05 in the univariate test, depicted in [Fig 2](#fig2){ref-type="fig"} as a heat map. The heat map provides an overview of the different lipid signals (reported as a combination of the retention time and mass/charge \[m/z\]) and their relative intensity, in terms of overexpression (in red) or underexpression (in green), in RP versus NRP sera. These results help highlight the differential lipid patterns between RP and NRP sera and are summarized in [Table 1](#tbl1){ref-type="table"}.Figure 1Partial least squares discriminant analysis score plots based on the lipidomics data. Responders (RPs) (represented as full diamonds) and not responders (NRPs; represented as open diamonds) before treatment (t0). The panels show partial least squares discriminant analysis score plots for the analyzed lipids, in particular the phosphatidylcholine/sphingomyelin class (A), phosphatidylethanolamine class (B), phosphatidylglycerol class (C), and phosphatidylserine class (D).Figure 2Heat map showing the relative intensity of the 65 differential serum lipids (listed on the right) of each sample (listed at the bottom) before treatment (t0). Samples are divided in 2 groups: RP and NRP. Lipid levels are indicated by a color code: high (red) and low (green). See [Fig 1](#fig1){ref-type="fig"} for abbreviations.Table 1Significant lipids obtained from statistical analysis (VIP \>1.5; *P* \< .05) in RPs and NRPs at the t0 time pointRT_m/zVIPNRPsRPs*t* test valueMeanSDMeanSDPCs/SMs**14.79_727.861.8618.036.2823.843.910.03716.14_495.72.599.881.5313.492.420.00115.72_480.422.271.460.622.240.390.008**13.44_787.522.13333.9556.02183.28155.440.01113.51_798.841.962.214.718.476.020.025**13.86_842.901.710.080.251.881.260.0001**12.57_830.921.700.220.481.010.930.03412.58_806.351.870.250.431.531.780.04212.51_812.582.210.020.070.290.260.00814.75_757.371.831.722.140.000.000.03814.91_782.881.930.110.361.531.780.02514.04_715.121.890.040.140.400.500.047PEs9.53_812.961.9222.9015.9341.2420.470.04810.80_478.631.784.408.7215.317.550.0139.83_723.001.783.156.7712.809.440.023**11.08_528.612.081.494.7120.8125.010.028**11.54_750.092.460.632.017.787.040.0079.67_796.812.230.932.9617.0719.230.0189.23_502.712.397.477.170.000.000.01011.18_532.482.057.559.030.000.000.03212.35_454.711.960.732.316.067.270.0439.43_764.262.156.607.410.000.000.0248.01_555.831.923.244.220.000.000.04610.10_731.772.210.000.007.108.620.0187.60_792.301.913.814.980.000.000.04711.27_939.112.160.000.003.704.670.02312.36_808.911.980.000.003.244.610.039PGs2.55_337.052.117.6610.1334.4031.770.0236.22_543.152.071.605.0715.3116.870.0265.77_763.481.862.738.6522.9828.480.0483.16_311.302.011.153.669.5410.760.03412.14_912.392.149.6910.560.000.000.0202.79_367.712.049.1210.560.000.000.0275.83_719.642.540.000.0013.0512.300.0043.34_877.711.921.936.1114.6216.730.0405.96_913.522.330.000.009.7410.600.0102.73_627.941.707.519.940.000.000.0502.25_798.512.020.000.0020.0428.360.0392.71_501.432.340.000.008.529.190.0097.16_807.462.320.000.006.226.780.010PSs13.60_782.522.3548.2337.83104.0252.040.01815.05_741.502.4411.119.6524.7911.200.01312.92_879.502.453.657.0318.0114.250.01312.84_815.032.492.955.1818.4616.200.01113.26_822.492.434.197.3820.4216.660.01417.99_600.692.132.403.9710.049.650.03610.48_840.462.087.759.910.000.000.04313.03_844.462.7812.3610.110.000.000.00313.45_786.542.5011.7310.590.712.030.01118.56_601.862.114.044.400.391.120.03813.09_874.692.047.738.800.762.160.04514.40_838.032.0410.6613.790.000.000.04512.85_841.742.120.812.568.5610.510.03817.02_688.962.230.561.797.078.230.02614.85_596.552.260.551.749.2010.950.02513.81_716.642.220.782.466.977.660.02816.79_744.772.012.483.290.000.000.05013.76_748.402.470.000.005.365.990.01210.50_467.352.230.000.004.435.760.02614.58_798.732.290.000.003.664.590.02218.36_614.292.082.343.070.000.000.04818.81_810.592.032.713.580.000.000.04914.83_443.052.450.000.002.893.280.01319.61_732.992.430.000.003.203.680.01412.03_992.422.032.413.170.000.000.048[^1][^2]

Biomarker confirmation {#sec3.2}
----------------------

To further validate the reliability of the highlighted biomarkers, an independent validation analysis was performed through targeted liquid chromatograph tandem mass spectometry. Results confirmed the lower levels in NRP of 5 differentially expressed lipids (*P* \< .05) that were identified as follows: SM (d18:2/18:1) at m/z = 727.86; lysophosphatidylcholine (LPC;16:0/0:0) at m/z = 496.22; LPC (15:1(9z)/0:0) at m/z = 480.42; lysophosphatidylethanolamine (LPE;22:5/0:0) at m/z = 528.6; and PC (40:2) at m/z = 842.90. These 5 lipids were regarded as the more reliable predictive biomarkers and quantified at 14 and 28 days to evaluate their prognostic value. As shown in [Fig 3](#fig3){ref-type="fig"}, PC (40:2), the 2 LPCs, and SM confirmed their lower levels in NRP with respect to RP during the entire therapy (*P* \< .05). Conversely, the levels of LPE varied during CRT. No significant difference between males and females was found in the highlighted biomarkers (data not shown).Figure 3Histograms reporting the relative abundance of potential biomarkers in RPs and NRPs during chemoradiation therapy (CRT). Relative abundances of phosphatidylcholine (PC; 40:2), lysophosphatidylcholine (LPC;16:0/0:0), LPC (15:1 (9Z)/0:0), sphingomyelin (SM; d18:2/18:1), and lysophosphatidylethanolamine (LPE;22:5/0:0) are shown, respectively, before treatment (t0), during CRT (t14), and at the last therapy day (t28). See [Fig 1](#fig1){ref-type="fig"} for abbreviations.

Predictive power of lipid biomarkers {#sec3.3}
------------------------------------

[Figure 4](#fig4){ref-type="fig"}A shows the receiver operating characteristic curve generated combining the 5 validated lipids. The area under the curve is 0.95, showing good sensitivity and specificity in discriminating between RP and NRP. The 100 cross-validations performed show the predicted class probabilities of each sample, as reported in [Fig 4](#fig4){ref-type="fig"}B, underlying the good predictivity of the proposed model (*P* = .03) in suggesting patients who may better respond to therapy.Figure 4Predictive power of 5 validated lipids at the t0 time point. (A) Receiver operating characteristic curve generated combining the 5 validated lipids; (B) predicted class probabilities (RP or NRP) of each sample across the 100 cross-validations and the related confusion matrix generated. See [Fig 1](#fig1){ref-type="fig"} for abbreviations.

Discussion {#sec4}
==========

Predictive response biomarkers to neoadjuvant CRT in LARC could personalize treatment strategy to improve response rate and survival outcomes. In this study, we focus on serum lipids to define a discriminatory profile able to predict CRT response in LARC. Despite the small sample size analyzed, our results indicate 5 lipids that drive the separation of RP and NRP. We found that LPE (22:5/0:0), SM (d18:2/18:1), LPC (16:0/0:0), LPC (15:1(9z)/0:0), and PC (40:2) are significantly lower in NRP at t0, whereas the LPE level significantly increases in NRP during CRT. The involvement of these lipids in radioresistance may be supported by the known correlation between human phosphatidylethanolamine-binding protein 4 (hPEBP4) and inhibition of apoptosis.[@bib14], [@bib15], [@bib16] Qiu et al have already demonstrated that hPEBP4 is a predictive marker of radioresistance in rectal cancer by activating Akt in a reactive oxygen species--dependent manner.[@bib17], [@bib18]

PC (40:2) is lower in NRP compared with RP before and during treatment, probably resulting from dysregulation of choline metabolism, a known metabolic hallmark associated with oncogenesis and cancer progression.[@bib19] Moreover, we highlighted low levels of LPCs in NRP, which is consistent with several studies that correlate higher blood LPC levels with reduced risk of cancer,[@bib18] thus suggesting that LPCs may represent a useful circulating biomarker for early detection of CRC.[@bib20] The low levels of SM in NRP may be due to the high activity of SM, resulting in high levels of ceramide. Even if ceramide is involved in cell-cycle arrest, apoptosis, and senescence in CRC cells,[@bib21], [@bib22] its degradation product, sphingosine1P, induces cell proliferation and angiogenesis and triggers cell motility.[@bib23] Bearing in mind the limitations of this pilot study, these results provide novel insights regarding lipid metabolism in the modulation of CRT response in LARC patients. If confirmed in a more extensive clinical cohort, these biomarkers could represent a useful tool for predicting outcome as part of efforts to personalize therapy.

Supplementary data {#appsec1}
==================
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[^1]: Bold type indicates confirmed biomarkers. Lipids are reported as a combination of RT_m/z.

[^2]: NRP, not responder; PC, phosphatidylcholine; RP, responder; RT_m/z, retention time and mass/charge; SM, sphingomyelin; SD, standard deviation; PE, phatidylethanolamine; PG, phosphatidylglycerol; PS, phosphatidylserine; VIP, variable important for the projection.
